Similar articles

• Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

  Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML. Raper SE, et al. J Inherit Metab Dis. 1998;21 Suppl 1:119-37. doi: 10.1023/a:1005369926784. J Inherit Metab Dis. 1998. PMID: 9686350
• Gene therapy death prompts review of adenovirus vector.

  Marshall E. Marshall E. Science. 1999 Dec 17;286(5448):2244-5. doi: 10.1126/science.286.5448.2244. Science. 1999. PMID: 10636774 No abstract available.
• A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.

  Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM, Batshaw ML. Raper SE, et al. Hum Gene Ther. 2002 Jan 1;13(1):163-75. doi: 10.1089/10430340152712719. Hum Gene Ther. 2002. PMID: 11779420
• [Gene therapy for ornithine transcarbamylase (OTC) deficient mice].

  Shimada T, Saheki T. Shimada T, et al. Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2674-8. Tanpakushitsu Kakusan Koso. 1995. PMID: 8584719 Review. Japanese. No abstract available.
• [Gene therapy for ornithine transcarbamylase deficiency].

  Matsuda I, Kiwaki K, Komaki S, Hoshide R, Matsuura T, Endo F. Matsuda I, et al. Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2759-64. Tanpakushitsu Kakusan Koso. 1995. PMID: 8584733 Review. Japanese. No abstract available.